Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$0.15 - $0.63 $1,590 - $6,678
-10,600 Reduced 42.23%
14,500 $2,000
Q3 2022

Nov 14, 2022

SELL
$0.52 - $3.08 $12,376 - $73,304
-23,800 Reduced 48.67%
25,100 $16,000
Q2 2022

Aug 15, 2022

SELL
$1.9 - $4.18 $119,510 - $262,922
-62,900 Reduced 56.26%
48,900 $119,000
Q1 2022

May 16, 2022

BUY
$3.54 - $8.3 $85,668 - $200,860
24,200 Added 27.63%
111,800 $452,000
Q4 2021

Feb 14, 2022

SELL
$7.69 - $19.66 $1.36 Million - $3.48 Million
-176,800 Reduced 66.87%
87,600 $702,000
Q3 2021

Nov 15, 2021

BUY
$12.22 - $21.28 $2.43 Million - $4.23 Million
198,700 Added 302.44%
264,400 $5.1 Million
Q2 2021

Aug 11, 2021

BUY
$9.0 - $15.94 $591,300 - $1.05 Million
65,700 New
65,700 $907,000

Others Institutions Holding PLXP

About PLx Pharma Inc.


  • Ticker PLXP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 29,137,700
  • Description
  • PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other asp...
More about PLXP
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.